Max India Sets Up Carbamezapine Facility
Indian pharmaceutical company Max India has set up the first integrated carbamezapine manufacturing facility in the country, according to the Marketletter's sources. Hindustan Ciba-Geigy and Sarabhai Chemicals currently formulate carbamezapine, an antiepilepsy agent. However, Max India will be the first company to synthesize the drug from the basic stage, it is claimed.
The carbamezapine unit is part of Max India's multipurpose chemical synthesis facility in Karnataka in southern India, with an investment of 350 million rupees ($9.8 million). Trial production of the drug is underway and the company expects to commence commercial manufacture this month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze